FLDM - Fluidigm Corporation Stock Trading

With shrinking revenues, unprofitable operations, and only $45.4 million in cash against trailing-12-month operating expenses of $115.4 million, cell analysis hardware company Fluidigm (NASDAQ: FLDM) might not seem like an obvious candidate for investment now. It took a beating in the recent...

After receiving an emergency use authorization from the Food and Drug Administration (FDA) last month, Fluidigm (NASDAQ: FLDM) reported that its saliva-based test for the novel coronavirus that causes COVID-19 is being run at two Clinical Laboratory Improvement Amendments (CLIA) certified ...

CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm C...